Clover Health Investments, Corp. filings document the company’s Medicare Advantage insurance business, physician enablement technology, operating results, governance, and material events. Recent 8-K reports furnish earnings releases, guidance updates, Medicare Advantage enrollment information, Regulation FD presentations, and supplemental shareholder Q&A materials related to financial performance and business priorities.
Proxy materials cover annual meeting matters, board and governance disclosures, executive compensation, equity awards, and related stockholder voting items. Other current reports document officer transitions, principal financial and accounting officer appointments, compensatory arrangements, and formal disclosures connected to the company’s remote-first corporate structure and public-company reporting obligations.
Clover Health Investments, Corp. (CLOV) Interim CFO Joseph Clay Thornton sold 4,591 Class A common shares on October 15, 2026, at a weighted average price of $4.68 per share; the sales occurred in multiple transactions at prices from $4.67 to $4.68. The shares were sold to cover tax withholding tied to vesting of 6.25% of his restricted stock units under the company’s required sell-to-cover arrangement, rather than as discretionary trades. Thornton directly held 1,244,935 shares after the sale. The transaction was reported under a Rule 10b5-1 plan.
Clover Health Investments, Corp. (CLOV) reported that Conrad Wai, identified as CEO of Counterpart Health, sold 23,627 shares of Class A common stock on October 15, 2026, at a weighted average price of $4.68 per share. The shares were sold in multiple transactions priced from $4.67 to $4.68. The sale covered tax withholding tied to vesting of 6.25% of restricted stock units granted to Wai on October 15, 2024; the company’s equity plans required tax withholding to be funded through a “sell to cover” transaction, which the footnote says was not discretionary. The sale was reported under a Rule 10b5-1 plan.
After the sale, Wai directly held 1,042,072 shares. A separate holding entry lists 1,170,056 shares in a trust for his family, of which he is a co-trustee. The remaining RSUs vest quarterly in equal installments of 6.25%, with final vesting scheduled for October 15, 2028, subject to continued service on each vesting date.
Clover Health Investments, Corp. reported that Jamie L. Reynoso, its CEO, Medicare Advantage, sold 18,273 Class A shares on October 15, 2026, at a weighted average price of $4.68 per share; individual sale prices ranged from $4.67 to $4.68. The sale covered tax withholding tied to quarterly vesting and was mandated under the issuer’s equity plans, not discretionary. The transaction was reported under a Rule 10b5-1 plan, and Reynoso held 2,774,417 shares directly after the sale. The vesting involved 6.25% of restricted stock units granted October 15, 2024; final vesting is set for October 15, 2028, subject to continued service.
Andrew Toy, an officer of Clover Health Investments, Corp. (CLOV), gave notice of a proposed sale of 60,765 Class A common shares for October 15, 2026, with an approximate market value of $284,380.2. The proposed sale is intended to cover tax withholding obligations tied to restricted stock unit vesting and settlement; the remarks say it is not discretionary. Prior three-month sales listed were 62,711 shares on July 15, 87,798 on August 10, and 318,806 on October 1, each identified as a 10b5-1 plan sale.
Clover Health Investments, Corp. officer Joseph Clay Thornton reported a proposed sale of 4,487 shares of Class A common stock, with an aggregate market value of $20,999.16, on October 15, 2026. The sale is listed as a 10b5-1 plan sale and is described as a non-discretionary “sell to cover” transaction for tax withholding tied to restricted stock unit vesting and settlement. Thornton also reported sales of 4,630 shares on July 15, 2026, and 17,775 shares on August 17, 2026.
Clover Health Investments, Corp. (CLOV) reports officer Conrad Wai’s proposed sale of 23,463 shares of Class A common stock, with an approximate sale date of October 15, 2026, and an aggregate market value of $109,806.84. The notice says the proposed sale is a “sell to cover” transaction for tax withholding tied to vesting and settlement of restricted stock units, and is not discretionary.
Clover Health Investments, Corp. (CLOV) officer Karen M. Soares reported a proposed sale of 14,341 shares of Class A common stock, with an approximate sale date of October 15, 2026, and an aggregate market value of $67,115.88. The shares relate to restricted stock units, and the remarks describe the proposed sale as a sell-to-cover transaction for tax withholding obligations, not a discretionary transaction. The notice also lists prior sales under a 10b5-1 plan: 10,519 shares on July 15, 2026; 51,700 shares on July 20, 2026; and 6,846 shares on September 15, 2026.
Clover Health Investments, Corp. (CLOV) reports that Officer Jamie Reynoso proposes to sell 17,858 shares of Class A common stock on October 15, 2026. The shares are restricted stock units from the issuer received as compensation. Reynoso says the proposed sale is a sell-to-cover transaction to fund tax withholding tied to vesting and settlement, and is not a discretionary transaction.
Clover Health Investments, Corp. (CLOV) said CMS awarded its Medicare Advantage PPO plans 5 Stars and its HMO plan 4.5 Stars for 2027; the ratings affect payment year 2028. The 5-Star PPO plans will be able to enroll beneficiaries year round.
Through the first half of 2026, Medicare Advantage membership grew approximately 48% year over year to more than 157,000 members, with approximately 98% enrolled in PPO plans. Clover also reported a HEDIS score of 4.82 out of 5 Stars, ranking #1 among non-SNP PPO plans with over 2,000 members, for the third year in a row.
Clover Health Investments, Corp. (CLOV) CEO, Medicare Advantage Jamie L. Reynoso sold 2,006 shares of Class A common stock on October 7, 2026, at a weighted average price of $4.63 per share. The sale was made under a Rule 10b5-1 trading plan adopted on March 12, 2026. Reynoso directly held 2,792,690 shares after the sale.